slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,568
Current window 44,461-44,490
Pages 2,019
Rows per page 30
Component
44,461-44,490 of 60,568
13
Includes a footnote citation for the methodology definitions.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
15
The slide shows baseline characteristics for a clinical trial, confirming that the treatment and placebo groups are well-matched.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
16
The table displays percentages for various categories of adverse events (AEs) and treatment-emergent adverse events (TEAEs).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
33
Data includes adjusted means, 95% confidence intervals, p-values, and percentage differences for various motor and respiratory domains.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
05
The table compares NYCB's performance at two different dates (9/30/22 and 12/31/23) against a peer median as of 9/30/23.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
07
Includes non-GAAP reconciliations note and rounding note.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
08
Includes non-GAAP adjustments and profitability metrics.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
09
Includes footnotes explaining specific line items and non-GAAP metrics.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
14
The table compares NYCB (as of Dec 31, 2023) against industry benchmarks (as of Sept 30, 2023).New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
19
The slide highlights that NYCB remains well-capitalized despite ongoing goodwill impairment assessments.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
24
The table segments the portfolio by percentage of rent-regulated units, showing loan counts, balances, unit counts, LTV, and DSCR.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Solution1 hit
26
UPB stands for Unpaid Principal Balance.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Solution1 hit
27
Includes footnotes regarding DSCR and LTV calculations.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Solution1 hit
29
Includes a footnote referencing page 30 for additional Warehouse information.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Solution1 hit
30
Includes a stacked bar chart for commitments, a table for market share, and a pie chart for collateral breakdown.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Solution1 hit
35
Includes SBNY acquisition impact and prior acquisitions.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
36
The slide presents specific quantitative targets for FY2024.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Guidance1 hit
39
Includes a footnote regarding merger-related items.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
41
Includes reconciliations for equity, assets, and various return ratios.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
42
New York Community Bancorp | Results Presentation Deck | 42 slidesNew York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
08
The slide uses a Gantt-style visualization to represent drug development stages.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a structured table to contrast two distinct patient populations (ALK+ vs ROS1+) across three lines of therapy (1L, 2L, 3L+).Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
14
The slide uses a matrix-style comparison to highlight the superior/differentiated profile of the 4th generation inhibitor NVL-655.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
16
Includes a formula for Selectivity index and a legend for various compound mutations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
17
The slide provides a detailed breakdown of patient enrollment across different dose cohorts (15mg to 200mg QD) for the NVL-655 clinical trial.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
18
Data cut-off: 8 Aug 2023. Includes detailed breakdown of prior ALK TKI therapies.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
20
Data cut-off: 8 Aug 2023. Includes detailed breakdown of response by mutation type and prior treatment history.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
24
Data cut-off: 8 Aug 2023. N=93 treated patients.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
26
The slide outlines a clinical trial design with specific patient cohorts (2a-2d) and study objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
28
The slide uses a timeline-based framework to contrast 1L and 2L+ treatment landscapes and their associated clinical challenges.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit